Tesaro's $101 million series B to fund rolapitant PhIII and build oncology portfolio
This article was originally published in Scrip
Executive Summary
In what is the largest strictly venture-funded financing of the year so far, Tesaro - an oncology-focused biotech company - has raised $101 million in a series B round.